Brain derived neurotrophic factor (BDNF) in cardiometabolic physiology and diseases;Kardiyometabolik fizyoloji ve hastalıklarda beyinden türemiş nörotrofik faktör (BDNF)

Anadolu Kardiyoloji Dergisi

Volumn 12, Issue 8, 2012, Pages 684-688

  Taşçi, Ilker ^a   Kabul, Hasan Kutsi ^a   Aydoǧdu, Aydoǧan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Atherosclerosis; Brain derived nerve growth factor; Cardiovascular disease; Diabetes mellitus; Dyslipidemia

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE; ENDOTHELIN; FIBROBLAST GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; LYMPHOKINE; MONOKINE; NERVE GROWTH FACTOR; NEUROTROPHIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; RESISTIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN NERVE CELL; BRAIN TISSUE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL GROWTH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENERGY METABOLISM; GLUCOSE UTILIZATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULIN METABOLISM; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID METABOLISM; LIPOPROTEIN SYNTHESIS; METABOLIC DISORDER; PERIPHERAL NERVOUS SYSTEM; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; METABOLISM;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CORONARY ARTERY DISEASE; CORONARY VESSELS; HUMANS;

EID: 84870561324     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2012.221     Document Type: Review

References (50)

1. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes 2006; 55 Suppl 2: S145-S154.
2. Taşçi I, Doǧru T, Naharci I, Erdem G, Yilmaz MI, Sönmez A, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007; 115: 428-432.
3. Erdem G, Doǧru T, Taşçi I, Sönmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 289-292.
4. Taşçi I, Erdem G, Özgür G, Tapan S, Doǧru T, Genç H, et al. LDL- cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009; 204: 222-228.
5. Kim HJ, Kim SK, Shim WS, Lee JH, Hur KY, Kang ES, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 81: 42-49.
6. Kiliç T. Is leptin an independent risk factor for development of left ventricular hypertrophy in obese hypertensive patients? Anadolu Kardiyol Derg 2008; 8: 347-349.
7. Taşçi I. Apelin, prediabetes and atherosclerosis. Exp Clin Endocrinol Diabetes 2011; 119: 457-458.
8. Doǧru T, Sönmez A, Taşçi I, Yilmaz MI, Erdem G, Ertürk H, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007;21:173-175.
9. Sönmez A, Celebi G, Erdem G, Tapan S, Genç H, Taşçi I, et al. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 179-183.
10. Taşçi I, Erdem G, Tapan S. The relation of ADMA and apelin to endothelial dysfunction and angiogenesis in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 86: e37-e38.
11. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24: 1217-1281.
12. Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 2000; 127: 4531-4540.
13. Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T, et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 2005; 112: 2114-2120.
14. Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A, et al. BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol Genomics 2006; 24: 191-197.
15. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26: 115-123.
16. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One 2010; 5: e10099.
17. Jung SH, Kim J, Davis JM, Blair SN, Cho HC. Association among basal serum BDNF, cardiorespiratory fitness and cardiovascular disease risk factors in untrained healthy Korean men. Eur J Appl Physiol 2011; 111: 303-311.
18. Krabbe KS, Mortensen EL, Avlund K, Pedersen AN, Pedersen BK, Jørgensen T, et al. Brain-derived neurotrophic factor predicts mortality risk in older women. J Am Geriatr Soc 2009; 57: 1447-1452.
19. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228-239.
20. Hiltunen JO, Laurikainen A, Väkevä A, Meri S, Saarma M. Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischaemia and reperfusion. J Pathol 2001; 194: 247-253.
21. Liu Y, Sun L, Huan Y, Zhao H, Deng J. Application of bFGF and BDNF to improve angiogenesis and cardiac function. J Surg Res 2006; 136: 85-91.
22. Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005; 102: 169-171.
23. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728-734.
24. Lorgis L, Amoureux S, de Maistre E, Sicard P, Bejot Y, Zeller M, et al. Serum brain-derived neurotrophic factor and platelet activation evaluated by soluble P-selectin and soluble CD-40-ligand in patients with acute myocardial infarction. Fundam Clin Pharmacol 2010; 24: 525-530.
25. Jiang H, Liu Y, Zhang Y, Chen Z Y. Association of plasma brain- derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris. Biochem Biophys Res Commun 2011; 415: 99-103.
26. Caporali A, Emanueli C. Cardiovascular actions of neurotrophins. Physiol Rev 2009; 89: 279-308.
27. Meuchel LW, Thompson MA, Cassivi SD, Pabelick CM, Prakash YS. Neurotrophins induce nitric oxide generation in human pulmonary artery endothelial cells. Cardiovasc Res 2011; 91: 668-676.
28. Tsuchida A, Nonomura T, Nakagawa T, Itakura Y, Ono-Kishino M, Yamanaka M, et al. Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Diabetes Obes Metab 2002; 4: 262-269.
29. Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 2008; 25:130-139.
30. Teillon S, Calderon GA, Rios M. Diminished diet-induced hyperglycemia and dyslipidemia and enhanced expression of PPARalpha and FGF21 in mice with hepatic ablation of brain- derived neurotropic factor. J Endocrinol 2010; 205: 37-47.
31. Kuroda A, Yamasaki Y, Matsuhisa M, Kubota M, Nakahara I, Nakatani Y, et al. Brain-derived neurotrophic factor ameliorates hepatic insulin resistance in Zucker fatty rats. Metabolism 2003; 52: 203-208.
32. Duan W, Lee J, Guo Z, Mattson M P. Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. J Mol Neurosci 2001; 16: 1-12.
33. Öztekin S, Karakurt O, Yazihan N, Ünal I. Relationship of brain natriuretic peptide with metabolic syndrome parameters: an observational study. Anadolu Kardiyol Derg 2011; 11: 678-684.
34. Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Noguchi H, Taiji M. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Diabetes Obes Metab 2007; 9: 879-888.
35. Duan W, Guo Z, Jiang H, Ware M, Mattson M P. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003; 144: 2446-2453.
36. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50:431-438.
37. Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 2006; 55: 852-857.
38. Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care 2012; 35: 363-366.
39. Navaratna D, Guo SZ, Hayakawa K, Wang X, Gerhardinger C, Lo EH. Decreased cerebrovascular brain-derived neurotrophic factor- mediated neuroprotection in the diabetic brain. Diabetes 2011; 60: 1789-1796.
40. Tonra JR, Ono M, Liu X, Garcia K, Jackson C, Yancopoulos GD, et al. Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Diabetes 1999; 48: 588-594.
41. Tsuchida A, Nakagawa T, Itakura Y, Ichihara J, Ogawa W, Kasuga M, et al. The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice. Diabetologia 2001;44:555-566.
42. Zoladz JA, Pilc A, Majerczak J, Grandys M, Zapart-Bukowska J, Duda K. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men. J Physiol Pharmacol 2008; 59 Suppl 7: 119-132.
43. Pedersen BK, Pedersen M, Krabbe KS, Bruunsgaard H, Matthews VB, Febbraio MA. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009; 94: 1153-1160.
44. Karadurmuş N, Tapan S, Çakar M, Naharci I, Çelik T, Taşçi I, et al. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Clin Invest Med 2012; 35: E20-E26.
45. Duan W, Guo Z, Jiang H, Ware M, Mattson M P. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003; 144: 2446-2453.
46. Işik S, Cetin M, Ciçekçioǧlu H, Uçar O, Çetin ZG, Ozuǧuz U, et al. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure. Anadolu Kardiyol Derg 2011; 11: 523-529.
47. Aydoǧdu A, Taşçi I, Tapan S, Başaran Y, Aydoǧan U, Meriç C, et al. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28:722-725.
48. Söylemez N, Demirbaǧ R, Sezen Y, Yildiz A, Akpinar O. The levels of the leptin and adiponectin according to body mass index and their relationship with oxidative parameters. Anadolu Kardiyol Derg 2010; 10: 391-396.
49. Genç H, Doǧru T, Tapan S, Taşçi I, Bozoǧlu E, Gök M, et al. Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: the impact of metabolic syndrome. Clin Biochem 2012; 45: 92-95.
50. Zhang F, Chen J. Leptin protects hippocampal CA1 neurons against ischemic injury. J Neurochem 2008; 107: 578-587.